Department of Anesthesia, University of Calgary, 1403 29th St. N.W., Calgary, AB, T2N 2T9, Canada.
Department of Community Health Sciences, University of Calgary, Calgary, AB, Canada.
Can J Anaesth. 2017 Nov;64(11):1144-1152. doi: 10.1007/s12630-017-0952-7. Epub 2017 Aug 29.
Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) benefit patients with peritoneal carcinomatosis. Nevertheless, this therapy is associated with considerable postoperative pain due to the extensive abdominal incision. While epidural analgesia offers efficacious pain control, CRS and HIPEC therapy is associated with perioperative coagulopathy that may impact its use. The purpose of this retrospective study is to characterize the postoperative coagulopathy in this patient subset and to develop a model that will help predict those at risk.
Our database of patients treated with CRS and HIPEC (n = 171) was reviewed to assess perioperative changes in platelet count, international normalized ratio (INR), and partial thromboplastin time (PTT). Abnormal coagulation was defined by platelet count < 100 × 10·L, INR ≥ 1.5, or PTT ≥ 45 sec. Severe abnormality in coagulation was defined by platelet count < 50 ×10·L, INR > 2.0, and/or PTT > 60 sec. A logistic regression model was developed to determine if patient, disease, and/or surgical factor(s) were associated with the development of postoperative coagulopathy. Epidural catheter management in this patient population was also reviewed.
Significant differences (adjusted P < 0.007) were noted between median preoperative and postoperative platelet and INR values on postoperative days (POD) 0 through 6 and days 0 through 3, respectively. Highest observed median differences between preoperative and postoperative values showed a decrease in platelet count of 94 × 10·L (POD 2 and POD 3), an increase in INR of 0.2 (POD 0 to POD 2), and a decrease in PTT of 3.1 sec (POD 5). Coagulopathy and severe coagulopathy occurred in 38% and 4.7% of patients, respectively. Predictors of coagulopathy included intraoperative transfusion of packed red blood cells (PRBCs) and perhaps the peritoneal carcinomatosis index (PCI). Epidural catheters were inserted in 26 patients for a median [IQR] duration of 7.0 [5.0-7.0] days without complication. At the time of their removal, no blood products were required to correct abnormal coagulation values.
Altered coagulation may appear during the postoperative period in approximately 40% of our patients treated with CRS and HIPEC. Intraoperative transfusion of RBCs and possibly increased PCI are associated with abnormal postoperative coagulation. Close monitoring of coagulation parameters is required to help ensure safe removal of an epidural catheter.
细胞减灭术(CRS)和腹腔内热灌注化疗(HIPEC)使腹膜癌患者受益。然而,由于广泛的腹部切口,这种治疗与相当大的术后疼痛有关。尽管硬膜外镇痛提供了有效的疼痛控制,但 CRS 和 HIPEC 治疗与围手术期凝血功能障碍有关,这可能会影响其使用。本回顾性研究的目的是描述该患者亚群的术后凝血功能障碍,并建立一种有助于预测风险的模型。
我们对接受 CRS 和 HIPEC 治疗的患者数据库(n = 171)进行了回顾性分析,以评估血小板计数、国际标准化比值(INR)和部分凝血活酶时间(PTT)的围手术期变化。异常凝血定义为血小板计数<100×10·L、INR≥1.5 或 PTT≥45 秒。严重凝血异常定义为血小板计数<50×10·L、INR>2.0 和/或 PTT>60 秒。建立逻辑回归模型以确定患者、疾病和/或手术因素是否与术后凝血功能障碍的发生有关。还回顾了该患者人群中硬膜外导管的管理。
术后第 0 天至第 6 天和第 0 天至第 3 天,血小板和 INR 的中位数术前和术后值之间存在显著差异(调整后 P<0.007)。观察到的中位数术前和术后值之间的最大差异显示血小板计数下降 94×10·L(术后第 2 天和第 3 天),INR 增加 0.2(术后第 0 天至第 2 天),PTT 下降 3.1 秒(术后第 5 天)。凝血功能障碍和严重凝血功能障碍分别发生在 38%和 4.7%的患者中。凝血功能障碍的预测因素包括术中输注红细胞(PRBC),可能还有腹膜癌指数(PCI)。26 例患者插入硬膜外导管,中位[IQR]持续时间为 7.0[5.0-7.0]天,无并发症。在移除硬膜外导管时,不需要血液制品来纠正异常凝血值。
在接受 CRS 和 HIPEC 治疗的患者中,大约 40%的患者在术后期间可能出现凝血功能改变。红细胞输注和可能增加的 PCI 与术后异常凝血有关。需要密切监测凝血参数,以确保安全移除硬膜外导管。